Tianjin Lisheng PharmaceuticalLtd Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Fujun Wang

Chief executive officer

CN¥939.6k

Total compensation

CEO salary percentage	n/a
CEO tenure	6.8yrs
CEO ownership	0.02%
Management average tenure	4.3yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Strong Profits May Be Masking Some Underlying Issues

Mar 28

CEO

Fujun Wang (55 yo)

6.8yrs

Tenure

CN¥939,600

Compensation

Mr. Fujun Wang has been a Non-Independent Director of Tianjin Lisheng Pharmaceutical Co.,Ltd. since August 17, 2017 and serves as its General Manager.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Fujun Wang	GM & Non-Independent Director	no data	CN¥939.60k	0.022% CN¥ 1.0m
Jiaying Wang	Financial Director & Accounting Supervisor	2.6yrs	CN¥622.20k	0.017% CN¥ 814.5k
Feifei Ma	Secretary of the Board	10.4yrs	CN¥648.90k	0.017% CN¥ 814.5k
Changfeng Long	Chief Engineer & Deputy GM	4.3yrs	CN¥698.00k	0.017% CN¥ 814.5k
Xiaoyan Guo	Deputy General Manager	no data	no data	0.017% CN¥ 814.5k

4.3yrs

Average Tenure

45.5yo

Average Age

Experienced Management: 002393's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Fujun Wang	GM & Non-Independent Director	6.8yrs	CN¥939.60k	0.022% CN¥ 1.0m
Qian Wang	Chairman of the Supervisory Board & Director	6.5yrs	no data	0.017% CN¥ 814.5k
Qifei Zhuang	Non-Independent Director	2.3yrs	no data	no data
Kexiang Yu	Non-Independent Director	2.3yrs	no data	no data
Yilong Tang	Non-Independent Director	2.3yrs	no data	no data
Ying Lei	Independent Director	2.4yrs	CN¥60.00k	no data
Jianxin Fang	Independent Director	3.4yrs	CN¥60.00k	no data
Guangyan Shen	Supervisor	2.3yrs	no data	no data
Mei Zhang	Independent Director	3.4yrs	CN¥60.00k	no data
Liyan Zhu	Supervisor	1.8yrs	no data	no data
Ping Zhang	Chairman of the Board	1.5yrs	CN¥136.00k	0.022% CN¥ 1.0m
Hao Liu	Director	1.8yrs	no data	no data

2.3yrs

Average Tenure

52yo

Average Age

Experienced Board: 002393's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Tianjin Lisheng PharmaceuticalLtd Management

Management criteria checks 3/4

Key information

Recent management updates

Tianjin Lisheng Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2024

High number of new directors

High number of new and inexperienced directors

Tianjin Lisheng Pharmaceutical Co.,Ltd. Approves Executive Changes

Recent updates

Tianjin Lisheng Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2023)

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Strong Profits May Be Masking Some Underlying Issues

Full year 2023 earnings released: EPS: CN¥1.96 (vs CN¥0.51 in FY 2022)

Investor sentiment deteriorates as stock falls 20%

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥1.37 (vs CN¥0.23 in 3Q 2022)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) for CNY 87.8 million.

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 30 June 2023

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.67 in FY 2021)

Investor sentiment deteriorated over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.20 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 2Q 2021)

Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces Final Dividend on Share A for 2021, Payable on June 20, 2022

First quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.20 in 1Q 2021)

High number of new and inexperienced directors

Tianjin Lisheng Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021

Investor sentiment improved over the past week

Tianjin Lisheng Pharmaceutical Co.,Ltd. Approves Executive Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥1.03 in FY 2019)

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 24, 2021

New 90-day low: CN¥17.18

New 90-day low: CN¥18.39

New 90-day low: CN¥22.63

New 90-day low: CN¥24.15

New 90-day low: CN¥24.28

Third quarter earnings released

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥25.02

First half earnings released

New 90-day high - CN¥29.81

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 24, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age